Category Specific RSS

Categories: News

Healthia revenues surge 50% as Australians flock to allied health services

Allied healthcare services provider Healthia (ASX: HLA) has seen a significant growth for the first half of FY20, reporting a 50.2% rise in revenues which has also led the company to declare their maiden dividend. 

Compared to the corresponding H1 results for the year prior, Healthia reporting the significant jump to $44.2 million in revenue for the group (+50.2%), as well as a 33.7% rise in underlying EBITDA to $5.7m. Included in the good results was their maiden dividend distribution of 1 cent per share fully-franked.  

Key to the strong finish in 2019 for the Company was 5.8% organic growth in their physiotherapy division and 1.3% in their podiatry division. 

Listing on the ASX in September 2018 under the guidance of Chairman Glenn Richards, who previously chaired veterinary roll-up Greencross, Healthia consolidated the heavily fragmented physio and podiatry clinics to form Healthia, listing at an IPO issue price of $1.00 per share. 

With their consolidation of the My FootDr podiatry brand and AllSports physiotherapy brand, the Group has since acquired a further 19 health businesses funded by a $50 million finance facility where clinics have been acquired at an average multiple of 4.15x EBITDA. 

Bringing clinicians within the Healthia banner, the Company hosted their inaugural industry education conference on the Gold Coast in October which was attended by 437 clinicians and support staff who this year will also be joined by the 45 new graduates that have been hired in their 2020 graduate intake. 

Whilst Healthia’s H1 earnings highlight significant growth for the Company, there is likely more on the horizon with a further $23.3m available to fund further acquisitions. The earnings also did not take into account the newly launched 3D-printed orthotics laboratory in the United States which has the capacity to deliver USD $1 million in revenue from their single printer currently in operation, with the capacity for a further two in the same lab. 

On 14 January 2020, Emerald Financial released a ‘Buy’ recommendation on Healthia at $1.11 which can be viewed here. 

*Owners of this website are shareholders in a company mentioned in this article and have been engaged by them to assist in investor communications

Alfred Chan

Alfred Chan is a Business Reporter at The Sentiment specialising in ASX-listed small cap companies, a bloodstock enthusiast and former equities analyst.

Recent Posts

Semtech and EMASS Bring Intelligence to the Edge as AI Meets Long-Range IoT

Australia’s industrial and IoT sectors are racing toward smarter, more autonomous sensing and one of…

1 month ago

Control Bionics Moves to Fully Acquire NeuroBounce Program as EMG-Based Performance Tech Gains Momentum

As interest in neuromuscular activation tools accelerates across elite sport, Control Bionics Limited (ASX:CBL) is…

1 month ago

SKS Technologies Moves to Expand NSW Footprint With Delta Elcom Acquisition

Australia’s data-centre construction sector continues to surge on the back of cloud adoption, AI-driven computing…

2 months ago

Monash University Partners with HITIQ to Advance Concussion Science Using Smart Mouthguards

A major Australian research initiative is set to push forward global understanding of brain injury,…

2 months ago

Harris Technology targets return to profitability amid surging Refurbished Tech sales and Apple expansion

Following a successful FY25 which saw a boost in gross profit after launching its refurbished…

3 months ago

Pivotal Metals Secures $5.4M to Fast-Track Quebec Drill Program

Pivotal Metals (ASX:PVT) has locked in $5.4 million in fresh funding to accelerate exploration across…

3 months ago